Tuesday, December 1, 2020

ROTH Capital slashes price target on Corbus Pharmaceuticals Holdings Inc. [CRBP] – find out why.

Must read

NVIDIA (NVDA) Stock Lost After Q3 Results, Record Revenues Did Not Help

The graphics chip (GPU) manufacturer NVIDIA Corp. (NVDA) issued its report for the third quarter of the fiscal year 2021 after the close of...

Oil Futures Saw Below 1% Decline, OPEC Still To Decide Upon Production Cuts

On Monday, November 30, after a rise of 1.1 percent during Friday trading, price of oil futures declined -0.4 percent to $45.34 per barrel...

Death Toll In U.S. Could Reached 321,000 In A Month, Air Traveling Rose 22% This Week

In recent weeks, the outbreak of coronavirus has led to new travel restriction initiatives in a number of U.S. states and cities, including California,...

Spirit Airline (SAVE), United Airline (UAL) Stock Surged, Quicker Recovery Will Be The Key To Growth

Good news on the efficacy of COVID-19 vaccines confirms stocks from airlines that have been among the most impacted by social activity constraints. Optimism...

Corbus Pharmaceuticals Holdings Inc. [NASDAQ: CRBP] gained 2.94% on the last trading session, reaching $0.99 price per share at the time. The company report on October 23, 2020 that Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020.

As previously reported, lenabasum did not meet its primary efficacy endpoint in the study.


My #1 Stock Trade This Year (HINT: It's a COVID-19 Play)

Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.    

>> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer <<

Sponsored


Lenabasum was well tolerated with no new safety findings.

Corbus Pharmaceuticals Holdings Inc. represents 73.89 million in outstanding shares, while the company has a total market value of $83.49 million with the latest information. CRBP stock price has been found in the range of $0.94 to $0.995.

If compared to the average trading volume of 4.96M shares, CRBP reached a trading volume of 1368550 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Corbus Pharmaceuticals Holdings Inc. [CRBP]:

ROTH Capital have made an estimate for Corbus Pharmaceuticals Holdings Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 08, 2020. The new note on the price target was released on September 08, 2020, representing the official price target for Corbus Pharmaceuticals Holdings Inc. stock. Previously, the target price had yet another drop from $18 to $2.50, while Jefferies kept a Hold rating on CRBP stock.

The Average True Range (ATR) for Corbus Pharmaceuticals Holdings Inc. is set at 0.14, with the Price to Sales ratio for CRBP stock in the period of the last 12 months amounting to 11.60. The Price to Book ratio for the last quarter was 1.50, with the Price to Cash per share for the same quarter was set at 0.75.

Trading performance analysis for CRBP stock

Corbus Pharmaceuticals Holdings Inc. [CRBP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.27. With this latest performance, CRBP shares dropped by -39.51% in over the last four-week period, additionally sinking by -84.62% over the last 6 months – not to mention a drop of -81.35% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRBP stock in for the last two-week period is set at 18.77, with the RSI for the last a single of trading hit 28.42, and the three-weeks RSI is set at 28.02 for Corbus Pharmaceuticals Holdings Inc. [CRBP]. The present Moving Average for the last 50 days of trading for this stock 3.4941, while it was recorded at 0.9894 for the last single week of trading, and 5.6769 for the last 200 days.

Corbus Pharmaceuticals Holdings Inc. [CRBP]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Corbus Pharmaceuticals Holdings Inc. [CRBP] shares currently have an operating margin of -226.01. Corbus Pharmaceuticals Holdings Inc.’s Net Margin is presently recorded at -197.69.

Return on Total Capital for CRBP is now -375.38, given the latest momentum, and Return on Invested Capital for the company is -342.06. Return on Equity for this stock declined to -424.29, with Return on Assets sitting at -148.66. When it comes to the capital structure of this company, Corbus Pharmaceuticals Holdings Inc. [CRBP] has a Total Debt to Total Equity ratio set at 153.40. Additionally, CRBP Total Debt to Total Capital is recorded at 60.54, with Total Debt to Total Assets ending up at 19.22. Long-Term Debt to Equity for the company is recorded at 131.50, with the Long-Term Debt to Total Capital now at 51.89.

Reflecting on the efficiency of the workforce at the company, Corbus Pharmaceuticals Holdings Inc. [CRBP] managed to generate an average of -$506,764 per employee. Receivables Turnover for the company is 26.96 with a Total Asset Turnover recorded at a value of 0.75.Corbus Pharmaceuticals Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.10.

Corbus Pharmaceuticals Holdings Inc. [CRBP]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Corbus Pharmaceuticals Holdings Inc. posted -0.32/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRBP.

An analysis of insider ownership at Corbus Pharmaceuticals Holdings Inc. [CRBP]

There are presently around $45 million, or 75.90% of CRBP stock, in the hands of institutional investors. The top three institutional holders of CRBP stocks are: BLACKROCK INC. with ownership of 6,273,466, which is approximately 8.679% of the company’s market cap and around 4.93% of the total institutional ownership; KNOLL CAPITAL MANAGEMENT, LP, holding 5,045,870 shares of the stock with an approximate value of $5.01 million in CRBP stocks shares; and CARMIGNAC GESTION, currently with $3.74 million in CRBP stock with ownership of nearly 415.649% of the company’s market capitalization.

Positions in Corbus Pharmaceuticals Holdings Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 92 institutional holders increased their position in Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] by around 12,615,727 shares. Additionally, 36 investors decreased positions by around 2,180,184 shares, while 26 investors held positions by with 31,035,213 shares. The mentioned changes placed institutional holdings at 45,831,124 shares, according to the latest SEC report filing. CRBP stock had 43 new institutional investments in for a total of 3,573,365 shares, while 10 institutional investors sold positions of 559,660 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Oil Futures Saw Below 1% Decline, OPEC Still To Decide Upon Production Cuts

On Monday, November 30, after a rise of 1.1 percent during Friday trading, price of oil futures declined -0.4 percent to $45.34 per barrel...

Death Toll In U.S. Could Reached 321,000 In A Month, Air Traveling Rose 22% This Week

In recent weeks, the outbreak of coronavirus has led to new travel restriction initiatives in a number of U.S. states and cities, including California,...

Spirit Airline (SAVE), United Airline (UAL) Stock Surged, Quicker Recovery Will Be The Key To Growth

Good news on the efficacy of COVID-19 vaccines confirms stocks from airlines that have been among the most impacted by social activity constraints. Optimism...

NVIDIA (NVDA) Stock Lost After Q3 Results, Record Revenues Did Not Help

The graphics chip (GPU) manufacturer NVIDIA Corp. (NVDA) issued its report for the third quarter of the fiscal year 2021 after the close of...

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the DBTNews.com pre-market morning brief 100% free

We do not sell or share your information with anyone.